311 related articles for article (PubMed ID: 17259693)
1. Refractory anaemia with excess of blasts in transformation re-evaluated with the WHO criteria: identification of subgroups with different survival.
Breccia M; Latagliata R; Carmosino I; Gentilini F; D'Elia GM; Levi A; Natalino F; Frustaci A; De Cuia MR; Alimena G
Acta Haematol; 2007; 117(4):221-5. PubMed ID: 17259693
[TBL] [Abstract][Full Text] [Related]
2. Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals.
Germing U; Strupp C; Kuendgen A; Aivado M; Giagounidis A; Hildebrandt B; Aul C; Haas R; Gattermann N
Br J Haematol; 2006 Jan; 132(2):162-7. PubMed ID: 16398650
[TBL] [Abstract][Full Text] [Related]
3. Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal.
Breccia M; Latagliata R; Cannella L; Carmosino I; De Cuia R; Frustaci A; Stefanizzi C; Santopietro M; Alimena G
Leuk Res; 2009 Mar; 33(3):391-4. PubMed ID: 18676015
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications.
Lorand-Metze I; Pinheiro MP; Ribeiro E; de Paula EV; Metze K
Leuk Res; 2004 Jun; 28(6):587-94. PubMed ID: 15120935
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of 4 prognostic scoring systems in 197 myelodysplastic syndrome patients].
Rubio-Félix D; Giraldo MP; Perella M; Gimeno J; Franco E; Giralt M
Sangre (Barc); 1991 Dec; 36(6):463-9. PubMed ID: 1812580
[TBL] [Abstract][Full Text] [Related]
6. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
[TBL] [Abstract][Full Text] [Related]
7. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.
Germing U; Strupp C; Kuendgen A; Isa S; Knipp S; Hildebrandt B; Giagounidis A; Aul C; Gattermann N; Haas R
Haematologica; 2006 Dec; 91(12):1596-604. PubMed ID: 17145595
[TBL] [Abstract][Full Text] [Related]
8. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
[TBL] [Abstract][Full Text] [Related]
9. Re-evaluation of refractory anemia with excess blasts in transformation.
Ohyashiki K; Nishimaki J; Shoji N; Miyazawa K; Kimura Y; Ohyashiki JH
Leuk Res; 2001 Nov; 25(11):933-9. PubMed ID: 11597728
[TBL] [Abstract][Full Text] [Related]
10. Clinical aspects of the myelodysplastic syndromes (MDS) with special reference to refractory anemia with excess of blasts (RAEB).
Omine M; Yamauchi H
Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):800-10. PubMed ID: 2618556
[TBL] [Abstract][Full Text] [Related]
11. Proposals for the classification of the myelodysplastic syndromes.
Bennett JM; Catovsky D; Daniel MT; Flandrin G; Galton DA; Gralnick HR; Sultan C
Br J Haematol; 1982 Jun; 51(2):189-99. PubMed ID: 6952920
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of WHO classification and MDS 2000 classification in myelodysplastic syndromes].
Akiba M; Matsuda A; Misumi M; Yagasaki F; Bessho M
Rinsho Ketsueki; 2001 Dec; 42(12):1162-9. PubMed ID: 11828718
[TBL] [Abstract][Full Text] [Related]
13. Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals.
Strupp C; Gattermann N; Giagounidis A; Aul C; Hildebrandt B; Haas R; Germing U
Leuk Res; 2003 May; 27(5):397-404. PubMed ID: 12620291
[TBL] [Abstract][Full Text] [Related]
14. [Myelodysplastic syndrome--classification, prognosis and therapy].
Cermák J; Michalová K; Vítek A
Cas Lek Cesk; 2002 Sep; 141 Suppl():33-7. PubMed ID: 12428420
[TBL] [Abstract][Full Text] [Related]
15. Percentages of bone marrow blasts and chromosomal changes in patients with refractory anemia help to determine prognoses.
Iwabuchi A; Ohyashiki K; Ohyashiki JH; Kimura Y; Lin KY; Aizawa S; Nehashi Y; Miyazawa K; Yaguchi M; Toyama K
Int J Hematol; 1994 Oct; 60(3):207-13. PubMed ID: 7858240
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of c-myc p67 oncoprotein in patients with myelodysplastic syndromes in transformation to acute leukaemia.
Kyriakou D; Eliopoulos AG; Alexandrakis M; Kalokyri I; Eliopoulos GD
Haematologia (Budap); 1996; 28(1):1-7. PubMed ID: 9283897
[TBL] [Abstract][Full Text] [Related]
17. [Myelodisplasic syndromes diagnosed in a geriatric hospital: morphological profile in 100 patients].
Dewulf G; Gouin I; Pautas E; Gaussem P; Chaïbi P; Andreux JP; Siguret V
Ann Biol Clin (Paris); 2004; 62(2):197-202. PubMed ID: 15047472
[TBL] [Abstract][Full Text] [Related]
18. Myelodysplastic syndromes in patients under 50 years old: a single institution experience.
Breccia M; Mengarelli A; Mancini M; Biondo F; Gentilini F; Latagliata R; Mandelli F; Alimena G
Leuk Res; 2005 Jul; 29(7):749-54. PubMed ID: 15927670
[TBL] [Abstract][Full Text] [Related]
19. Clinical, hematological and histomorphological profile of myelodysplastic syndrome.
Nigam S; Rani S; Singh T; Gupta S; Rakheja D; Gaiha M
J Assoc Physicians India; 2001 Apr; 49():430-4. PubMed ID: 11762613
[TBL] [Abstract][Full Text] [Related]
20. [Chromosome abnormalities in myelodysplastic syndrome].
Fujita K; Mori H; Niikura H; Terada H; Shinohara T
Rinsho Byori; 1990 Aug; 38(8):911-6. PubMed ID: 2232253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
